Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Dual-targeting BCMA-CD19 CAR-T cell(Beijing GoBroad Hospital) in Pulmonary arterial hypertension associated with connective tissue disease: NCT06947473 Clinical Landscape Report 2026
15 October 2026
NCT06947473 clinical landscape for Pulmonary arterial hypertension associated with connective tissue disease: endpoints, sponsor, phase, geography, readouts…
9 min read
Dual-targeting BCMA-CD19 CAR-T cell(Beijing GoBroad Hospital) in Pulmonary Arterial Hypertension: NCT06947460 Clinical Landscape Report 2026
15 October 2026
NCT06947460 clinical landscape for Pulmonary Arterial Hypertension: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Datopotamab Deruxtecan in PD-L1 negative Triple Negative Breast Cancer: NCT06954480 Clinical Landscape Report 2026
15 October 2026
NCT06954480 clinical landscape for PD-L1 negative Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Glofitamab in Large B-cell lymphoma: NCT06956092 Clinical Landscape Report 2026
15 October 2026
NCT06956092 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anzutresgene Autoleucel in Melanoma, Cutaneous Malignant: NCT06946225 Clinical Landscape Report 2026
15 October 2026
NCT06946225 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dostarlimab-gxly in Endometrial Carcinoma: CTRI/2025/04/085913 Clinical Landscape Report 2026
15 October 2026
CTRI/2025/04/085913 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-2173 in Systemic Lupus Erythematosus: NCT06955598 Clinical Landscape Report 2026
15 October 2026
NCT06955598 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Busulfan in Acute Myeloid Leukemia: NCT06954987 Clinical Landscape Report 2026
15 October 2026
NCT06954987 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Disitamab Vedotin in Carcinoma of urinary bladder, invasive: NCT06957561 Clinical Landscape Report 2026
15 October 2026
NCT06957561 clinical landscape for Carcinoma of urinary bladder, invasive: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Trilaciclib Dihydrochloride in Advanced Triple-Negative Breast Carcinoma: NCT06955156 Clinical Landscape Report 2026
15 October 2026
NCT06955156 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Axatilimab-csfr in Triple Negative Breast Cancer: NCT06959537 Clinical Landscape Report 2026
15 October 2026
NCT06959537 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lutetium (177 Lu) Vipivotide Tetraxetan in Metastatic Clear Cell Renal Cell Carcinoma: NCT06959433 Clinical Landscape Report 2026
15 October 2026
NCT06959433 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…